CD38 and Miyoshi myopathy: CD38 up regulation is thought to be one of the most important factors in mediating resistance to checkpoint blockade in MM and other cancers.43–45 CD38-targeted biologics are currently used in the clinic to treat MM, but they do not mitigate the immunomodulating effects of CD38.